Breakthrough Technology

Breakthrough Technology

The standard 12-lead electrocardiogram (ECG or sometimes called EKG) is a diagnostic recording of cardiac electrical activity over time. The 12-lead ECG is cardiology's most frequently used screening and diagnostic tool. Over 200 million ECGs are obtained in the developed world each year, making it the most commonly performed cardiovascular diagnostic test. The ECG has a central role in screening and diagnosis of acute coronary syndromes (heart attack) and many other common forms of heart disease, and often provides the primary basis for critical therapeutic decisions.

Unknown by many, the standard ECG contains latent information about cardiac electrical activity that in total represents the three dimensional (3D) operation of the heart. However, today's standard 12-lead ECG merely represents that data as a series of 2-dimensional time and voltage readings, which must be synthesized into a 3D model of the heart operation by a clinician. It is very difficult, and in the case of some critical parameters impossible, for humans to perform this 3D synthesis in their mind.

NewCardio has developed a new patented and patent pending technology which can process this standard ECG data, and utilize and present it an easy to read format with additional 3D clinically significant diagnostic information. Importantly, no change in clinician practice of how ECG data is collected. Simply said - NewCardio does not change the standard practice for ECG collection.

The past 40 years have brought us remarkable gains in computational power. This creates an opportunity to extract substantially more diagnostically valuable information from the ECG signal. By continuing to develop appropriate mathematical algorithms and software, NewCardio believes that its proprietary 3D approaches can significantly enhance the ECG's diagnostic utility, reduce its complexity, and improve its ease of use for the medical professional. Results of first medical trials of NewCardio's technology at Harvard University Medical School and elsewhere indicate initial results to be very encouraging.